GLP1R and diabetic retinopathy: This is not the first time that topical administration of neuroprotective agents such as GLP-1 Receptor Agonists (Hernández et al., 2017), DPP-IV inhibitors (Hernández et al., 2016) and dual endothelin receptor antagonist Bosentan (Bogdanov et al., 2018) were shown to be useful in experimental models of diabetic retinopathy DR.